Drugs / Essential Aminoacids
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02145949 | Dec 2014 → Feb 2020 | muscular atrophy | University of Oregon | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04816071 | May 2021 | COVID-19 | University of Arkansas | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03784495 | Jan → Dec 2014 | muscular atrophy | Azienda di Servizi alla Persona di Pavia | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Essential amino acids | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04816071 ↗ |
| Known as | eAA | “Essential Amino Acids (EAA)” NCT02145949 ↗1“Essential Aminoacids (eAA)” NCT03784495 ↗ |